Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...

From late 2020 to the summer of 2024, Eli Lilly & Co. (NYSE ... For example, in 2016 Lilly was trading 13 times the trailing 12 months earnings and the market has increased its valuation each ...

Eli Lilly (NYSE:LLY) recently announced leadership transitions, including new roles for Ilya Yuffa, Patrik Jonsson, and ...

Have you assessed how the international operations of Eli Lilly (LLY) performed in the quarter ended March 2025? For this drugmaker, possessing an expansive global footprint, parsing the trends of ...

Eli Lilly (NYSE:LLY) harnessed significant operational performance during the latest quarter, reporting robust sales and net ...

Eli Lilly and Company LLY will report its first-quarter earnings on May 1, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $12.62 billion and $3.52 per share, ...

A consultancy’s new ranking of drug company R&D shows Eli Lilly has risen to the top of the drug development heap, while ...

Eli Lilly's Zepbound loses CVS coverage to Wegovy, prompting analyst debate on pricing pressures and long-term obesity market ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

Eli Lilly (NYSE:LLY) recently announced the impressive results of its SURMOUNT-5 trial, highlighting Zepbound's efficacy over ...